Proteomic signatures hold promise in pancreatic cancer therapy
The development of such a proteomic signature is known to be very beneficial in carrying out the desired action in the target patients and its validation may prove it to be a potential therapeutic marker for treatment approach as well as in clinical evaluation.
Rate this! 1-5 stars
8 August 2012, Australia (Kamagrarx.co): The companies Biodesix, which is a CO-based company and the pharmaceutical company Globe Immune are being collaborating to build a diagnostic test for the identification of those pancreatic cancer patients, who are more susceptible to the treatment response.
Biodesix that develops diagnostics dependent on the MS (mass spectroscopy) technology has discovered a proteomic signature subsequent to the investigation of clinical trial data of the cancer vaccine of GlobeImmune, that is code named GI-4000 for use in pancreatic cancer.
This custom-made approach of the two companies is found to kick start and alacrity the clinical trials in addition to enhancing the result outcome in the tumor patients.
In the phase II clinical evaluation study, the cancer patients suffering from Ras mutant positive adenocarcinoma have been only given the medication gemcitabine or in conjugation with GI-4000. The prime objective behind the study was to measure the efficacy of the drug GI-4000 in preventing the recurrence of the disease complication.
As per the results the drug GI-4000 when used in combination with gemcitabine has been found to enhance the recurrence-free survival as well as one-year survival.
And, with the aid of ProTS mass spectrometry-dependent technology approach of Biodesix, the investigators were successful in finding a proteomic signature in nearly 50 % of the patients, who took the drug combination and showed an improved drug response to the drug GI-4000.
The senior vice president of R&D and chief medical officer of GlobeImmune, Dr. David Apelian said that the use of Biodesix’s approach has discovered a new potential diagnostic implication for selection of patients who are more likely to get advantage from the GI-4000 therapeutic measure.
He also added that the company is very contented and thrilled with the results and plan to continue the collaborative research work with them.
100 Railway Street
Sydney, NSW, AUSTRALIA- 2766
For more: http://www.kamagrarx.co